During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.

Though COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in 2024 and so far in 2025, driven by ...